We therefore conducted a systematic review and meta-analysis, collating the most recent evidence into the prior information, aiming to establish the impact of SGLT2 inhibitors on UTIs and genital infections in patients with type 2 diabetes. Here, SLC5A2 is linked to type 2 diabetes mellitus.